Daniel W. Tan
Experienced in Lung Metastases

Daniel W. Tan

11 Hospital Crescent, 
Singapore, SG 
Experienced in Lung Metastases
11 Hospital Crescent, 
Singapore, SG 
OverviewLocationsClinical Research

Overview

Daniel Tan practices in Singapore, Singapore. Mr. Tan is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Tissue Biopsy, and Laryngectomy.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lung Metastases.

Gender
Male

Locations

11 Hospital Crescent, Singapore, 169610, Singapore

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2

172 Total Publications

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
Journal: The Journal of thoracic and cardiovascular surgery
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tan's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile